- By insider

EVP GPS, BD, & Licensing of Incyte Corp (30-Year Financial, Insider Trades) Vijay K Iyengar (insider trades) sold 5,116 shares of INCY on 01/25/2021 at an average price of $99 a share. The total sale was $506,484.

• Warning! GuruFocus has detected 5 Warning Signs with INCY. Click here to check it out.

• INCY 15-Year Financial Data

• The intrinsic value of INCY

• Peter Lynch Chart of INCY

Incyte Corp is a biopharmaceutical company. It discovers, develops and commercializes proprietary therapeutics. Its product JAKAFI, a JAK1 and JAK2 inhibitor is used for treatment of patients with intermediate or high risk myelofibrosis. Incyte Corp has a market cap of $20.37 billion; its shares were traded at around $93.000000 with and P/S ratio of 8.29. GuruFocus has detected 3 severe warning signs with Incyte Corp. .

Directors and Officers Recent Trades:

• EVP, Head of Discovery Chem Yao Wenqing sold 21,545 shares of INCY stock on 01/25/2021 at the average price of $100. The price of the stock has decreased by 7% since.

• EVP & Chief Medical Officer Steven H Stein sold 3,795 shares of INCY stock on 01/25/2021 at the average price of $100. The price of the stock has decreased by 7% since.

• EVP GPS, BD, & Licensing Vijay K Iyengar sold 5,116 shares of INCY stock on 01/25/2021 at the average price of $99. The price of the stock has decreased by 6.06% since.

• EVP & General Manager US Barry P Flannelly sold 2,744 shares of INCY stock on 01/25/2021 at the average price of $100. The price of the stock has decreased by 7% since.

For the complete insider trading history of INCY, click here

.This article first appeared on GuruFocus.